Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cheri Cartagena

Physician Assistant, Medical Hagerstown, MD Physician Assistant

NPI 1538310230 CMS profile 10709145

11236 Robinwood Dr Ste 204, Hagerstown, MD 21742

Open in the dashboard

General payments

$13,710

623 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cheri Cartagena of Hagerstown, MD is reported in the CMS Open Payments database as having received $13,710 across 623 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,028 137
2024 General $2,299 100
2023 General $4,046 198
2022 General $3,350 135
2021 General $986 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cheri Cartagena
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Cheri Cartagena were reported at $3,028. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Cheri Cartagena Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $986 $156 $41–$563 $132
2022 $3,350 $185 $55–$649 $149
2023 $4,046 $199 $58–$717 $160
2024 $2,299 $206 $62–$740 $164
2025 $3,028 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $2,900 115 payments
  2. AbbVie, Inc. $2,285 105 payments
  3. Novartis Pharmaceuticals Corporation $1,259 65 payments
  4. Lilly USA, LLC $1,033 54 payments
  5. Regeneron Healthcare Solutions, Inc. $950 33 payments
  6. LEO Pharma Inc. $879 54 payments
  7. Pfizer Inc. $748 39 payments
  8. Incyte Corporation $667 29 payments
  9. UCB, Inc. $548 20 payments
  10. E.R. Squibb & Sons, L.L.C. $436 17 payments
  11. Other $2,006 92 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,096 613 payments
  2. Education $614 10 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $3,064 115 payments
  2. RINVOQ $933 37 payments
  3. SKYRIZI $854 38 payments
  4. ADBRY $851 52 payments
  5. DUPIXENT $739 21 payments
  6. TALTZ $706 43 payments
  7. COSENTYX $691 36 payments
  8. LITFULO $668 34 payments
  9. CIBINQO $665 35 payments
  10. OPZELURA $521 27 payments
  11. Other $5,505 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,169

Median for Physician Assistant: 241

Drug cost

$1,202,126

Median for Physician Assistant: $4,110

Branded share of claims

18.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Risankizumab-Rzaa Brand 18 $412,673
Otezla Apremilast Brand 31 $154,690
Opzelura Ruxolitinib Phosphate Brand 45 $103,338
Cibinqo Abrocitinib Brand 18 $99,326
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $96,961
Dupixent Syringe Dupilumab Brand 23 $95,269
Humira(Cf) Pen Adalimumab Brand 13 $93,963
Adbry Tralokinumab-Ldrm Brand 22 $81,538
Enstilar Calcipotriene/Betamethasone Brand 18 $25,508
Tacrolimus Generic 36 $7,835

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$71,860

Of which drugs: $701

Medicare patients

567

Average age 73

Services billed

2,106

280 women, 287 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 34%
Ischemic heart disease 24%
Depression 24%
Chronic kidney disease 20%
Atrial fibrillation 17%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $667
$667 — —
RINVOQ
  • AbbVie, Inc. $241
$241 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $187
$187 13 —
OPZELURA
  • Incyte Corporation $115
$115 45 —
Bimzelx
  • UCB, Inc. $101
$101 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

623 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record